Global variation in SARS-CoV-2 proteome and its implication in pre-lockdown emergence and dissemination of 5 dominant SARS-CoV-2 clades by Patro, L Ponoop Prasad et al.
Infection, Genetics and Evolution 93 (2021) 104973
Available online 18 June 2021
1567-1348/© 2021 Elsevier B.V. All rights reserved.
Research paper 
Global variation in SARS-CoV-2 proteome and its implication in 
pre-lockdown emergence and dissemination of 5 dominant 
SARS-CoV-2 clades 
L Ponoop Prasad Patro 1, Chakkarai Sathyaseelan 1, Patil Pranita Uttamrao 1, 
Thenmalarchelvi Rathinavelan * 
Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Telangana 502285, India   
A R T I C L E  I N F O   
Keywords: 
SARS-CoV-2 viromics 
Highly recurring mutations 




A B S T R A C T   
SARS-CoV-2 is currently causing major havoc worldwide with its efficient transmission and propagation. To track 
the emergence as well as the persistence of mutations during the early stage of the pandemic, a comparative 
analysis of SARS-CoV-2 whole proteome sequences has been performed by considering manually curated 31,389 
whole genome sequences from 84 countries. Among the 7 highly recurring (percentage frequency≥10%) mu-
tations (Nsp2:T85I, Nsp6:L37F, Nsp12:P323L, Spike:D614G, ORF3a:Q57H, N protein:R203K and N protein: 
G204R), N protein:R203K and N protein: G204R are co-occurring (dependent) mutations. Nsp12:P323L and 
Spike:D614G often appear simultaneously. The highly recurring Spike:D614G, Nsp12:P323L and Nsp6:L37F as 
well as moderately recurring (percentage frequency between ≥1 and <10%) ORF3a:G251V and ORF8:L84S 
mutations have led to4 major clades in addition to a clade that lacks high recurring mutations. Further, the 
occurrence of ORF3a:Q57H&Nsp2:T85I, ORF3a:Q57H and N protein:R203K&G204R along with Nsp12: 
P323L&Spike:D614G has led to 3 additional sub-clades. Similarly, occurrence of Nsp6:L37F and ORF3a:G251V 
together has led to the emergence of a sub-clade. Nonetheless, ORF8:L84S does not occur along with ORF3a: 
G251V or Nsp6:L37F. Intriguingly, ORF3a:G251V and ORF8:L84S are found to occur independent of Nsp12: 
P323L and Spike:D614G mutations. These clades have evolved during the early stage of the pandemic and have 
disseminated across several countries. Further, Nsp10 is found to be highly resistant to mutations, thus, it can be 
exploited for drug/vaccine development and the corresponding gene sequence can be used for the diagnosis. 
Concisely, the study reports the SARS-CoV-2 antigens diversity across the globe during the early stage of the 
pandemic and facilitates the understanding of viral evolution.   
1. Introduction 
The severe acute respiratory syndrome virus 2 (SARS-CoV-2) 
pandemic outbreak has so far claimed several millions of lives. Treating 
the SARS-CoV-2 pandemic is the biggest challenge being faced by the 
world today. Although SARS-CoV-2 is expected to have a slow mutation 
rate due to its sophisticated proof reading mechanism (Pachetti et al., 
2020), it can incorporate changes in the genome (Catanzaro et al., 2020; 
Garcia, 2020; Lucas et al., 2001) to escape from the host immune de-
fences. A comparative analysis of 31,389 clinically relevant SARS-CoV-2 
whole genome sequences obtained from 84 countries are exploited here 
to accelerate the identification of universal vaccine candidates and drug 
targets. A country wise local proteome repository has been created and 
subjected to multiple sequence alignment to analyze the position spe-
cific recurrence of each amino acid variation, henceforth referred to as 
percentage frequency (see Methods), in the SARS-CoV-2 whole 
proteome. 
The SARS-CoV-2 genome has 10 open reading frames (ORFs) flanked 
by 5′UTR and 3′UTR (Kim et al., 2020; Wu et al., 2020). Upon entering 
into the host by either direct membrane fusion or receptor-mediated 
endocytosis, the ORF1ab is translated into two large polyproteins 
(PP1a and PP1ab) with the utilization of the host translational ma-
chinery. PP1a consists of non-structural proteins (Nsps) 1 to 11, 
whereas, the PP1ab comprises of Nsps 1 to 16 (except Nsp11) and are 
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translated from the genomic RNA. The matured Nsp1 to Nsp16 are 
produced with the help of two viral encoded cysteine proteases, namely, 
the papain-like protease (PLpro) (proteolyzes Nsps 1–3) and the main 
protease (Mpro or 3CLpro) (proteolyzes Nsps 4–16). The Nsps 7–16 act as 
the replication machinery that enables the synthesis of the viral genome. 
The subgenomic RNAs from S, ORF3a, E, M, ORF6, ORF7a, ORF7b, 
ORF8, N and ORF10 coding regions are involved in the translation of 
virion structural and accessory proteins. While the proteins synthesized 
by ORF3a, ORF6, ORF7a, ORF7b, ORF8 and ORF10 are designated as 
accessory proteins, the proteins from S, E, M and N are designated as 
structural proteins (Kim et al., 2020). ORF10 is being utilized in the 
diagnostics to differentiate SARS-CoV from SARS-CoV-2 (Khailany et al., 
2020; Takahiko Koyama DPaLP, 2020). 
SARS-CoV-2 whole proteome analysis encompassing the above pro-
teins indicates that 7, 28 and 2081 unique mutations exhibit high 
(≥10%), moderate (≥1–<10%) and low (≥0.01–<1%) percentage fre-
quency respectively during the early stage of the pandemic (December 
2019-May 17, 2020). 5 major clades have evolved encompassing these 
mutations. Among the mutations, Spike:D614G and Nsp12:P323L are 
occurring in nearly 75% of the sequences soon after their first appear-
ance in January 2020 (GISAID ID: EPI_ISL_422425) indicating their 
evolutionary advantage. Interestingly, R203K and G204R present in 
nucleoprotein are found to be co-occurring (dependent) mutations. The 
study also reports the presence of several deletions and co-occurring 
mutations that recur at a moderate percentage frequency. As the enve-
lope protein, Nsp4, Nsp9 and Nsp10 are less heterogeneous compared 
with the rest of the proteins, they can be good vaccine/drug targets. 
Thus, the results presented here would help in identifying the potential 
therapeutic targets. It may further have an impact on correlating the 
mutations with the viral evolution and virulence. 
2. Methods 
The whole genome sequences (WGS) obtained from the clinical 
samples collected from the diverse geographical background were 
downloaded from the NCBI (Benson et al., 2011) (3,730 sequences) 
(TableSD1A.xlsx) and GISAID (Shu and McCauley, 2017) (27,659 se-
quences) (TableSD1B.xlsx) (deposited on or before May 17, 2020). 
31,389 sequences were considered to analyze SARS-CoV-2 proteomic 
diversity (in the above-mentioned proteins) across 84 countries. Sub-
sequently, the dataset was manually curated to create the local database. 
The viral genome sequences with more than 15,000 bases (half of the 
entire viral genome) were alone considered in the creation of the data-
base. Note that as there is no link between the WGS deposited in the 
NCBI and GISAID, there is a possibility of sequence(s) duplication in the 
local database. The genomic sequences were then translated into indi-
vidual proteins (Kim et al., 2020; Wu et al., 2020) (as mentioned in the 
Introduction) by considering the first published SARS-CoV-2 proteome 
as the reference (herein onwards, reference sequence) using an in-house 
script. Note that if any translated region contained an undefined amino 
acid (due to the presence of one or more undefined nucleotides (“N”) in 
the coding region), the region was not considered for the analysis. 
However, the remaining coding regions were considered for the analysis 
(Table SD2.xlsx). 
The country wise mutational analysis specific to each protein was 
analyzed through multiple sequence alignment (MSA) using CLUSTAL 
OMEGA (Sievers and Higgins, 2014). It is worth mentioning that the 
sequences were available for the following countries: England, Wales, 
Scotland, France, Luxembourg, Netherlands, Spain, Belgium, Germany, 
Italy, Czech, Austria, Ireland, Denmark, Latvia, Greece, Hungary, Swe-
den, Switzerland, Poland, Turkey, China, Japan, Malaysia, Russia, Saudi 
Arabia, Singapore, South Korea, Taiwan, Hong Kong, Thailand, Viet-
nam, Georgia, India, Iran, Israel, USA, Canada, South Africa, Congo, 
Australia, Argentina, Brazil, Chile, Uruguay, Colombia, Iceland, 
Portugal, Norway, Finland, Estonia, Slovenia, Lithuania, Slovakia, 
Belarus, Kuwait, Nepal, Pakistan, Mexico, Ghana, Algeria, Senegal, New 
Zealand, Peru, Ecuador, Panama, Cambodia, Tunisia, Serbia, Romania, 
Croatia, Philippines, Indonesia, UAE, Jordan, Qatar, Bangladesh, 
Brunei, Kazakhstan, Sri Lanka, Costa Rica, Guam, Gambia and Egypt. 
Prior to the MSA, the 26 proteins (non-structural (Nsps 1 to 16), 
structural (Spike, Envelope, Membrane and Nucleocapsid) and acces-
sory proteins (ORF3a, ORF6, ORF7a, ORF7b, ORF8 and ORF10)) (Kim 
et al., 2020) encoded by the genomic and subgenomic RNAs of SARS- 
CoV-2 were segregated individually and stored country wise in the 
database. 
2.1. Calculation of the percentage frequency 
The country wise MSA alignments were manually verified for each of 
the 26 proteins and subjected to position wise amino acid variation 
analysis using in-house scripts. When an amino acid at a particular po-
sition changes to a different amino acid, the number of such changes was 
counted to calculate the frequency of mutation in each country. A mu-
tation was considered as recurrent (viz., the mutation that does not occur 
by chance) only if the summation of the country wise percentage fre-
quency (PF) (Eq. (1)) of that particular mutation is (occurs at least 3 
times) 0.01%. 
Percentage frequency of an amino acid mutation(%)
=
Summation of an amino acid mutation frequency in different countries
Total number of sequences
x100
(1) 
The recurrent mutations were further classified into three categories: 
highly recurring (HR), moderately recurring (MR) and low recurring 
(LR). A mutation was considered as highly (dominant) or moderately 
recurring when it occurs at the percentage frequency ≥10% or ≥1 and 
<10% respectively. On the other hand, a mutation was considered as a 
low recurrent when it occurs at the percentage frequency between 0.01 
and <1% (frequency in the range of 3-314). 
Further, the mutation susceptibility of a protein in terms of number 
of recurrences and number of positions undergoing mutations are 
quantified using the following equations: 
Percentage mutation per protein (PMP)
=
Total number of mutations recurring at least 3 times in the protein
Total number of mutations found in the proteome
× 100
(2)  
Percentage mutable positions in a protein(PMPP)
=
Number of positions mutated at least 3 times in the protein
Length of the protein
× 100 (3)  
2.2. Construction of phyloproteomic tree 
Initially, the whole genome sequences that do not have undefined 
nucleotides (‘N’) were translated to 11,198 single sequences with each 
containing 26 translated proteins (5’UTR, 3’UTR, ORF1ab stemloop 1, 
ORF1ab stemloop 2, ORF10 stemloop 1 and ORF10 stemloop 2 were 
excluded). The phyloproteomic trees corresponding to the countries that 
occupy top 10 positions in terms of number of SARS-CoV-2 sequences 
were constructed: USA (number of sequences = 1372), Australia (219), 
Belgium (142), China (135), Denmark (156), France (180), Iceland 
(118), India (107), Netherlands (173) and UK (981). The sequences were 
subsequently subjected to alignment using MAFFT (Katoh and Standley, 
2013) and the phyloproteomic tree was constructed using maximum 
likelihood method in IQ-TREE software (Nguyen et al., 2015). Itol tool 
(Letunic and Bork, 2019) was used to visualize and analyze the 
phylogram. 
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3. Results 
31,389 sequences have been considered to analyze SARS-CoV-2 
proteome diversity across 84 countries. Functions of all the twenty-six 
SARS-CoV-2 proteins are provided in Table S1. Further, the PMP of 
the 26 proteins falls in the following order: Nsp12 (19.900%) > Spike 
(16.657%) > N protein (15.911%) > ORF3a (11.505%) > Nsp2 
(10.867%) > Nsp13 (4.265%) > Nsp3 (4.242%) > ORF8 (3.969%) >
Nsp6 (3.816%) > Nsp5 (1.387%) > Nsp1 (1.210%) > Nsp14 (0.963%) 
> M protein (0.961%) > Nsp4 (0.930%) > Nsp15 (0.895%) > Nsp16 
(0.543%) > Nsp7 (0.452%) > ORF7a (0.437%) > Nsp8 (0.289%) >
ORF6 (0.169%) > ORF10 (0.148%) > E protein (0.136%) > Nsp9 
(0.124%) > ORF7b (0.108%) > Nsp10 (0.106%) > Nsp11 (0.008%). 
Similarly, PMPP falls in the following order: ORF3a (44%) > ORF7a 
(38.842%) > ORF8 (35.537%) > N protein (35.083%) > ORF10 
(31.578%) > ORF6 (29.508%) > ORF7b (27.906%) > Nsp2 (25.508%) 
> Nsp1 (25.414%) > Nsp9 (19.298%) > Nsp15 (17.579%) > E protein 
(17.333%) > Nsp13 (17.109%) > Nsp5 (16.938%) > Nsp6 (16.838%) >
Nsp3 (16.341%) > Nsp8 (16.08%) > Nsp16 (15.719%) > Spike 
(15.632%) > Nsp12 (14.576%) > Nsp7 (14.285%)≥ Nsp11 (14.285%) 
> Nsp4 (13.572%) > M protein (13.513%) > Nsp14 (13.446%) > Nsp10 
(7.857%). Taking into account the mutation recurrence frequency as 
well as the number of positions exhibiting variations in each protein, it 
can be suggested that ORF3a and Nsp10 are the proteins that have the 
highest and lowest susceptibility to the mutation respectively (Fig. 1). 
The Tables SD3-SD28.xlsx provide country wise percentage fre-
quency of SARS-CoV-2 amino acid mutations. 
3.1. Mutations with high recurrence 
In Nsp2, T85I mutation recurs at the percentage frequency of 20.43% 
in 47 countries (Fig. 2A & B) indicating the pre-lockdown global spread 
of I85 (54% occupancy among the mutations in Nsp2). This mutation is 
found at the highest recurring level in USA with nearly 56% of its se-
quences having this mutation. Similarly, L37F in Nsp6 has a percentage 
frequency > 11.98% (Fig. 2A). 59 countries possess these mutations 
(Fig. 2C). Further, P323L in Nsp12 that is located in the proximity of the 
Nsp8-Nsp12 binding site (Fig. S1, PDB ID: 6YYT) is found in 71 countries 
(except Brunei, Croatia, Iran, Malaysia, South Korea, Nepal, Philippines, 
Turkey, Pakistan, Tunisia, Guam and Uruguay) out of 84 countries 
considered here with a high recurrence (percentage frequency of 
69.47%) (Fig. 2A & D). Prevalence of this mutation is also reported 
earlier (Pachetti et al., 2020; Chand et al., 2020; Ugurel et al., 2020; 
Zhao et al., 2020). 
In spike protein, D614G (present in the S1 subunit flanked by the 
receptor binding site) (Fig. 2A & E) mutation has become the most 
dominant mutation as reported earlier (Daniloski et al., 2020; Klumpp- 
Thomas et al., 2020; Korber et al., 2020; Zhang et al., 2020a) with the 
percentage frequency of 69.20%. Totally, 70 countries (except 14 
countries, namely, Brunei, Panama, Cambodia, Tunisia, Malaysia, 
Nepal, South Korea, Philippines, Iran, Pakistan, Ghana, Uruguay, Qatar 
and Guam) have this mutation (Fig. 2A & E). In addition to above, Q57H 
in ORF3a is found to be the highly recurring mutation with the per-
centage frequency of 24.43% in 51 countries (Fig. 2A & F). N protein co- 
mutations (dependent), R203K and G204R are also found to occur with a 
Fig. 1. Bar diagram illustrating the mu-
tation susceptibility (%) of 26 proteins 
(See Supplementary Table S1 for func-
tions). (A) Considering the mutation count 
from individual proteins, the mutation sus-
ceptibility (Eq. (2)) falls in the following 
order: Nsp12 > Spike >N protein > ORF3a 
> Nsp2 > Nsp13 > Nsp3 > ORF8 > Nsp6 >
Nsp5 > Nsp1 > Nsp14 > M protein > Nsp4 
> Nsp15 > Nsp16 > Nsp7 > ORF7a > Nsp8 
> ORF6 > ORF10 > E protein > Nsp9 >
ORF7b > Nsp10 > Nsp11. (B) When the 
mutation position count is considered, the 
mutation susceptibility (Eq. (3)) falls in the 
following order: ORF3a > ORF7a > ORF8 >
N protein> ORF10 > ORF6 > ORF7b >
Nsp2 > Nsp1 > Nsp9 > Nsp15 > E protein >
Nsp13 > Nsp5 > Nsp6 > Nsp3 > Nsp8 >
Nsp16 > Spike > Nsp12 > Nsp7 > Nsp11 >
Nsp4 > M protein > Nsp14 > Nsp10.   
L.P.P. Patro et al.                                                                                                                                                                                                                               
Infection, Genetics and Evolution 93 (2021) 104973
4
high percentage frequency (~23.6%). Both of them co-exist in 63 
countries and occur at a high percentage frequency of 12.5% in England 
followed by Wales (3.34%) and Scotland (1.01%) (Fig. 2A, G & H). 
Thus, Nsp2:T85I, Nsp6:L37F, Nsp12:P323L, Spike:D614G, ORF3a: 
Q57H, N protein:R203K and G204R have occurred at a high recurrence 
during the early stage of the pandemic. 
3.2. Evolution of new lineages with moderate and low recurring mutations 
3.2.1. Protein encoded by ORF1ab 
In addition to the abovementioned 7 highly recurring mutations, 28 
moderately recurring mutations have been observed during the early 
stage of the pandemic. For instance, the exchange between the nega-
tively charged amino acids D75 and E75 in Nsp1 occurs at a moderate 
percentage frequency of ~1% (Fig. 3). Further, co-occurring 
Fig. 2. Emergence and dissemination of the mutations that highly recur during pre-lockdown period: A) Heat map representing the country wise percentage 
frequency of 7 highly recurring mutations. B-H) Global distribution of (represented by percentage frequency) highly recurring mutations: B) Nsp2:T85I, C) Nsp6: 
L37F, D) Nsp12:P323L, E) Spike:D614G, F) ORF3a:Q57H, G) N protein:R203K and H) N protein:G204R. 
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(dependent) K141, S142 and F143 deletions in Nsp1 are found to recur 
above 0.35% PF. Strikingly, G82-V86 is yet another stretch in Nsp1 that 
is prone to undergo mutations. For instance, the deletion of M85 
(~0.34%) is found with the highest occurrence in England. Similar to 
K141, S142 and F143 deletions, G82 deletion is also found at the low 
recurrence (PF = 0.1%). Independent deletion of V84 and V86 is also 
found in certain countries (TableSD3.xlsx). 
Similarly, P585S (~4.1%), I559V (~3.8%), deletion of D268 
(~2.87%) and G212D (~2.64%) in Nsp2 are found at a moderate per-
centage frequency. A total of 26 countries (England, Wales, Scotland, 
France, Belgium, Germany, Ireland, Greece, Sweden, Singapore, 
Taiwan, Thailand, Vietnam, India, Jordan, USA, Australia, Chile, Ice-
land, Netherlands, Portugal, Finland, Canada, Ghana, Congo and Brazil) 
undergo P585 to S585 mutation (Fig. 3) indicating the spread of the 
SARS-CoV-2 variant having this mutation during pre-lockdown period. 
Very interestingly, the same countries/sequences undergo I559 to V559 
mutation with a nearly similar percentage frequency. These two muta-
tions occur at the highest percentage frequency in England (~2.9–3%) 
followed by Wales (0.3%) and Australia (0.2–0.3%) (Fig. 3). 
Nsp3 mutations that are found with a moderate percentage fre-
quency are: A58T which is present in the UBL1 domain of Nsp3 is the 
moderately recurring mutation with the percentage frequency of 1.8%, 
P153L (occurs at the percentage frequency in the range of 0.7% and 
0.26% respectively in USA and Australia) and T428I (England possesses 
the highest PF of 0.86%). Notably, these mutations do not occur in the 
PL-pro domain (PDB ID: 6WUU), which makes this domain a potential 
drug target in line with the earlier attempts (Zhou et al., 2020) (Fig. S1, 
TableSD5.xlsx). 
In Nsp4, the exchange between the aromatic amino acids F308 and 
Y308 is the highest among the (Nsp4) mutations, which occurs with a 
moderate percentage frequency (1.2%). Nsp5 or main protease is an 
attractive target to treat SARS-CoV-2 as it plays a major role in 
producing the functional forms of Nsp4 to Nsp16 (Zhang et al., 2020b). 
Although the catalytic site and N-terminal finger of Nsp5 are conserved, 
G15S located in the chymotrypsin-like domain is recurring at a moderate 
PF of 1.6% (Fig. 3). Luckily, the structure of Mpro is available (PDB ID: 
6LU7) which indicates that this mutation does not occur either at the 
catalytic site or at the N-terminal finger (important for the recognition of 
the target protein) or at the dimeric interface indicating the conserva-
tion of its functional mechanism (Fig. S1). Since this mutation occurs on 
the surface exposed region of Nsp5, it may have an influence on the 
interaction with other virion protein(s) as well as the host protein(s). 
3.3. Mutations in the replication machinery 
Nsp7 to Nsp16 are the replicase polyproteins and crucial for the 
protein replication. S25L is the only recurring mutation in Nsp7 (Fig. 3 
and TableSD9.xlsx). S25L of Nsp7 occurs at a moderate percentage 
frequency of 1.33%. Notably, this mutation occurs at the turn region of 
the alpha helical bundle of Nsp7, which interacts with Nsp8 (Fig. S1). 
Next, A97V of Nsp12 is a moderately recurring mutation (1.2%) (Fig. 3). 
In Nsp13, the exchange between the aliphatic A18 and V18 (PF = 1.1%), 
P504L (PF = 5.6%) and Y541C (PF = 5.8%) are found with the moderate 
recurrence (Fig. 3). F233L (~1.26%) and A320V of Nsp14 (~1.26%) are 
moderately recurring mutation (Fig. 3) which are found in the exori-
bonuclease (ExoN) and (guanine-N7)-methyl transferase (N7-Mtase) 
domains of Nsp14 respectively (Ma et al., 2015) (as seen in the Nsp10- 
Nsp14 SWISS-MODEL complex structure based on SARS-CoV which has 
the sequence identity more than 90% (PDB ID: 5C8S)) (Fig. S1). Inter-
estingly, Nsp8, Nsp9, Nsp10, Nsp11, Nsp15 and Nsp16 of the replication 
machinery do not have moderately or highly recurring mutations. 
Fig. 3. Heat map representing the country wise percentage frequency of 28 moderately recurring (MR) mutations. Note that, 52 countries have at least one of 
the MR mutations (percentage frequency between ≥1 and <10%). Among the 52 countries, Australia is found to have 28 out of the 28 MR mutations, followed by 
USA (27), England (24), Scotland (23) and Wales (22). 
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3.4. Moderately and low recurring mutations in the proteins encoded by 
SARS-CoV-2 subgenomic mRNA 
G251V of ORF3a protein is the moderately recurring mutation with 
the second highest percentage frequency (~9%) among the moderately 
recurring mutations and is highly occurring in England (PF = 5.18%) 
(Fig. 3).V13L of ORF3a is a moderately recurring mutation (PF = 2.6%) 
with England holding the top position followed by Wales and Scotland 
(Fig. 3). Additionally, H93Y and G196V in ORF3a (PF = 0.76%) are 
found to be low recurring mutations (Table S2). In M protein, T175M is a 
Fig. 4. (A-J) Phyloproteome analyses represent the pre-lockdown emergence and the dissemination of 5 major clades of SARS-CoV-2 across the countries that are top 
10 in terms of their SARS-CoV-2 sequence data. 
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moderately recurring mutation with the percentage frequency of 
~1.6%. The Envelope protein, ORF6, ORF7a, ORF7b and ORF10 do not 
have any mutations that recur at a moderate PF. L84S in ORF8 is the 
moderately recurring mutation with the upmost percentage frequency 
(~9.8%) among the moderately recurring mutations and is highly 
recurring in USA (PF = 5.93%). Additionally, S24L (PF = 2.2%) and 
V62L (PF = 1.2%) are the moderately recurring mutations in ORF8 
(Fig. 3). 
Notably, in N protein, S180, S183, S187, S188, S190, S193, S194, 
S197 and S202 present in a serine rich stretch (SR rich linker domain, 
residue number 180–202) change primarily to aliphatic/aromatic amino 
acids I, Y, L, L/P, I, I, L, L and N respectively. Among these, S193I, S194L 
and S197L recur with the percentage frequency in the range of 1 to 1.6% 
(moderate recurrence) (Fig. 3), whereas, S188L and S190I occur with 
the percentage frequency of 0.45% and 0.23% respectively (TableSD27. 
xlsx). Indeed, certain countries have percentage frequency more than 
1.5% for these mutations: S193I (the highest in Wales followed by En-
gland), S194I (the highest in Scotland followed by England, India and 
Wales) and S197L (the highest Australia followed by Scotland, England 
and Spain). Apart from these, P13L (N-terminal disordered region, the 
highest in Australia) (PF = 1.03%) and D103Y (PF = 1.05%) also occur 
at a moderate percentage frequency (Fig. 3). Notably, 11 recurring 
mutations (including R203K and G204R co-mutations) occur in the 
S180-R209 stretch of SR rich linker region, for which, the structural 
information is unknown (Fig. S1). 
Some notable substitutions, co-occurring mutations, deletions and 
insertions which occur with a low to moderate recurrence and may have 
a significant influence on the viral pathogenic mechanism are: co- 
deletion (dependent) of K141, S142 and F143, co-deletion (depen-
dent) of G82 and H83, D75E, co-occurring (dependent) S135N, Y136 
deletion and M85 deletion in Nsp1, D268 deletion, G212D, co-occurring 
(dependent) I559V and P585S, F10L, V198I, P91S, T166I, H237R, 
T371I, S211F and G339S in Nsp2, A58T, P153L and T428I in Nsp3, 
F308Y, T295I (0.3%) and M33I in Nsp4, G15S and K90R in Nsp5, S25L 
and S26F in Nsp7, A97V and A449V in Nsp12, A18V and co-mutation 
P504L & Y541C in Nsp13, F233L and A320V in Nsp14, V13L in 
ORF3a, S24L and A62L in ORF8, D936Y in spike and P13L, D103Y, 
S193I, S194L and S197L with a percentage frequency above 1% in 
nucleoprotein. Very interestingly, a deletion in ORF8 region is found in 
Singapore and Taiwan. In these sequences, the ORF8 encodes only 9 
amino acid peptide instead of the 121 long amino acid protein. This 
mutation is suggested to be associated with SARS-CoV-2 infection found 
in Taiwan and the Middle East countries (Gong et al., 2020). 
The Table S2 contains the list of above discussed low, moderate and 
high recurrent mutations found in the structural and accessory proteins 
of SARS-CoV-2. 
3.5. Evolution of five major clades of SARS-CoV-2 
Individual phyloprotemic trees generated here for top 10 countries 
(based on the sequences deposited) by considering the reference pro-
teome sequence (Genbank ID: NC_045512.2) as the root and the non- 
redundant proteome sequences which vary at least in one position of 
the SARS-CoV-2 proteome with respect to the reference sequence indi-
cate the region wise evolution of 5 major clades (Fig. 4 (A-J)) during the 
early stage of the pandemic. 3 of the clades are due to the high recurrent 
mutations [Nsp6:L37F (Clade 1), Spike:D614G (Clade 3) and Nsp12: 
P323L (Clade 4)] and one of the clade is due to the moderately recurring 
mutation [ORF8:L84S (Clade 2)]. The sequences devoid of the highly 
recurring mutations form a separate clade (Clade 5). Among these 
clades, the spike protein clade has the highest number of sub-clades as it 
is in the phase of overtaking the wild-type during the pre-lockdown 
time. Further, 4 major sub-clades of Clade 3 (Spike:D614G) have also 
emerged during the pre-lockdown. For instance, additional mutations in 
Spike:D614G (Clade 3a) have led to: Clade 3b (Nsp12:P323L), Clade 3c 
(Nsp12:P323L and ORF3a:Q57H), Clade 3d (Nsp12:P323L, ORF3a: 
Q57H & Nsp2:T85I) and Clade 3e (Nsp12:P323L & N protein:R203K & 
G204R). Simultaneous occurrence of Nsp6:L37F and ORF3a:G251V has 
led to Clade 1b. 
Intriguingly, individual phyloproteomic trees provide information 
about the clades that are prevalent in certain countries. The Clade 5 
(that lacks high recurrent mutations) followed by Clade 2 (which are 
deficient of Spike:D614G mutation) are found to be prevalent in China 
which is the epicenter of the pandemic. Similarly, Clades 3d & 2 and 
Clades 3b & 3e are prominent in USA and Europe respectively. However 
the Clade 3d is dominant in Denmark. In Australia, all the clades are 
found to occur with nearly similar frequency. The Clade 3c followed by 
Clade 1a are found to be highly recurring in India. 
3.6. Spike:D614G and Nsp12:P323L mutations are highly found in the 
hospitalized patients 
Not surprisingly, the available patient condition data for 1040 se-
quences (as on May 17, 2020) indicates that Spike:D614G and Nsp12: 
P323L are dominantly found in the hospitalized patients due to their 
surge after January 2020 (Fig. 5). Followed by these, ORF3a:Q57H is 
found in the hospitalized patients. In comparison to highly recurring 
mutations, moderately recurring mutations are found in relatively lesser 
frequency (lesser than 10-fold) in the hospitalized patients. Among the 
moderately recurring mutations, following mutations are found in the 
hospitalized patients in the following order of frequency: ORF8:L84S >
ORF3a:G251V > ORF8:S24L > N protein: S197L > Nsp4:F308Y. It is 
noteworthy that only a few sequences in GISAID have information about 
the mild, moderate or severe symptom of the patients. Thus, this point is 
not discussed in detail here. 
4. Discussion 
The SARS-CoV-2 pandemic is a major threat to the public health. 
Several attempts are being made to obtain a potential drug molecule or 
vaccine candidate with a broad coverage (Martin and Cheng, 2020; 
Poran et al., 2020; Shyr et al., 2020). Although the reasons behind 
variations in the vulnerability to SARS-CoV-2 infection between in-
dividuals are still unclear, the variations in the human (Hou et al., 2020) 
as well as the viral genome may have an important role in the degree of 
severity of SARS-CoV-2 infection between individuals. To this end, a 
comparative analysis of SARS-CoV-2 whole proteome has been per-
formed here by considering 31,389 whole genome sequences from a 
diverse clinical and geographical (84 countries) origin to identify the 
mutations that occur in 26 SARS-CoV-2 proteins. Prior to the analyses, a 
manually curated database has been created for the whole genome 
protein sequences (country wise and protein wise) and is subjected to 
the mutation analyses. 
The results indicate that 2116 mutations occur recurrently in SARS- 
CoV-2 proteome in 84 nations (Table S2). Among these, 7, 28 and 2081 
are highly, moderately and low recurring mutations respectively 
(Figs. 2, 3 and Table S2). The highly recurring mutations include Nsp2: 
T85I, Nsp6:L37F, Nsp12:P323L, Spike:D614G, ORF3a:Q57H, N protein: 
R203K and N protein:G204R which are found across 47, 59, 71, 70, 51, 
63 and 63 countries respectively (Fig. 2). Interestingly, R203K and 
G204R are co-occurring (dependent) mutations as they occur in nearly 
similar frequency in same countries. Among all the highly recurring 
mutations, Nsp12:P323L and Spike:D614G are found in majority of the 
countries (~69%). Intriguingly, some of these mutations are highly 
prevalent in certain countries compared to the rest of the mutations: 
P323L, D614G, R203K and G204R in England and P323L, D614G, Q57H 
and T85I in USA. The high recurrence of the above mutations clearly 
indicates that these mutations might have evolved very early and might 
have a positive selection pressure. 
Further, 28 mutations are found in moderate recurrence (Fig. 3) and 
are found in 78 countries. Australia has the highest number of moderate 
mutations (28 out of 28) followed by USA (27) and United Kingdom 
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(England, Wales and Scotland carry these moderately recurring muta-
tions in the range of 22–24) (Fig. 3). Denmark also has 14 of these 
moderately recurring mutations. Among the Asian countries, India and 
Taiwan carry the highest number (viz.,13) of moderate mutations. Chile 
has 13 moderate mutations. Most of the moderately recurring mutations 
are absent in African countries, perhaps due to the limited availability of 
the data. In addition to the moderately and highly recurring mutations, 
2081 mutations are found at a low recurrence (1%< PF ≥0.01%). 
Six SARS-CoV-2 proteins (Nsp2, Nsp6, Nsp12, Spike, ORF3a and N 
protein) have at least one of the highly recurring mutations and 10 
proteins (Nsp2, Nsp3, Nsp4, Nsp5, Nsp7, Nsp13, ORF3a, M protein, 
ORF8 and N protein) have at least one of the moderately recurring 
mutations. The rest of the proteins have only low recurrent mutations 
(Table S2). 
Seven HR (Fig. 2A), 2 MR (ORF8:L84S and ORF3a:G251V, Fig. 3) and 
sequences devoid of HR mutations have led to the emergence of 5 major 
clades and 5 sub-clades of SARS-CoV-2 during the early stage of the 
pandemic which have disseminated across many countries during the 
Fig. 5. Bar chart illustrating the relationship between patients’ condition with the (A) highly recurring and (B, C) moderately recurring mutations. Note that the 
color associated with the patients’ conditions are indicated alongside graph. 
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pre-lockdown period. Among them, Clade 2 has originated from the 
moderately recurring mutation ORF8:L84S and Clade 5 mainly possesses 
low recurring mutations. However, Nsp6:L37F has led to Clade 1a and 
its sub-clade 1b (ORF3a:G251V). Interestingly, 70% of proteome se-
quences are found under Clade 3 which encompasses 4 sub-clades 
emerging from Nsp12:P323L, ORF3a:Q57H, N protein:R203K & 
G204R and Nsp6:T85I mutations indicating their evolutionary 
advantage. 
Further, the structural (Fig. S1) and functional perspective of the 
SARS-CoV-2 protein mutations reported here provide some useful in-
formation for the therapeutics. The PL-pro domain and macrodomain of 
Nsp3 can be potential drug targets as they are less prone to mutations 
(Virdi et al., 2020). Occurrence of S25L mutation in Nsp7, which is in the 
proximity to Nsp7-Nsp8 binding interface and the proximity of Nsp12: 
P323L to the Nsp12-Nsp8 binding site indicate their possible role in 
modulating the viral replication mechanism. Further, majority of the 
amino acids in Nsp6 mutates either to F or to a more hydrophobic amino 
acid implicating the role of these mutations in host membrane manip-
ulations (Fig. S1). Similarly, Nsp16:P134S located in the cavity that is in 
proximity to the SAM binding site may have a role in replication mod-
ulation (PDB ID: 7BQ7) (Fig. S1). In general, the mutations in the 
replicase machinery, except Nsp12:P323L, occur with a low recurrence 
indicating their role in functional conservation and thus, could be po-
tential therapeutic targets. Interestingly, Spike:D614G, Spike:D936Y 
and ORF3a:V13L mutations are observed in potential B-cell or T-cell 
epitope regions (Grifoni et al., 2020), thus, may have an influence on the 
host defence mechanisms. Yet another notable point is a high mutability 
found in the SR stretch of the nucleoprotein which may have a role in 
host immune evasion (Gong et al., 2020; Li et al., 2020) (Fig. S1). 
Since the interaction between SARS-CoV-2 spike protein and ACE2 
receptor of the host is important for its entry into the host, one can 
envisage that ACE2 receptor polymorphism could influence the sus-
ceptibility and severity of the infection across different host population. 
Although a few studies have been carried out to address the role of 
expression and polymorphism of ACE2 receptor in SARS-CoV-2 infection 
susceptibility and severity (Hou et al., 2020; Cao et al., 2020; Sur-
yamohan et al., 2021; Hussain et al., 2020; Devaux et al., 2020; Benetti 
et al., 2020), the unavailability of ACE2 receptor sequence information 
limits the establishment of one-to-one correlation between the ACE2 
receptor polymorphism and spike protein variation and its implication 
in susceptibility and severity of the infection. 
As SARS-CoV-2 variants having Spike:D614G mutation (which has 
enhanced infectivity and transmissibility (Korber et al., 2020; Zhang 
et al., 2020c; Plante et al., 2021; Gobeil et al., 2021; Raghav et al., 
2020)) have conquered the wild-type across the globe, it is important to 
analyze the occurrence of high and moderate recurrent mutations along 
with Spike:D614G. Luckily, the availability of the mutations present in 
the SARS-CoV-2 proteome enables the understanding of the prevalence 
of certain mutations along with Spike:D614G (TableSD29.xlsx). For 
instance, Nsp2:T85I and ORF3a:Q57H (mostly occur together) along 
with Spike:D614G are found to be highly prevalent in USA (Nsp2:T85I 
and Spike:D614G = ~75% and ORF3a:Q57H and Spike:D614G =
~85%) and Denmark (Nsp2:T85I and Spike:D614G = ~72% and 
ORF3a:Q57H and Spike:D614G = ~76%) population. Intriguingly, 
these combinations are found with low prevalence in UK. Similarly, 
Spike:D614G and the co-mutations N protein:R203K and N protein: 
G204R are highly recurring in countries like Greece (78%), Portugal 
(68%), Russia (65%), UK (52%), Netherlands (35%) etc. Not surpris-
ingly, Spike:D614G and Nsp12:P323L are found together in all the 
countries with above 95%. Among the moderately recurring mutations, 
M protein:T175M along with Spike:D614G occur above 25% in the 
Netherlands. Similarly, N protein:S194L and Spike:D614G occur ~25% 
in India. 
In summary, the present investigation reveals the emergence of 5 
major divergence from the reference sequence (Genbank ID: 
NC_045512.2) quite early during the pandemic based on the recurring 
(high, moderate and low recurrence) mutations in the proteome of 
SARS-CoV-2 for the dataset considered in this investigation. The high 
and moderate recurrent mutations which are found ≥10% and ≥1- 
<10% frequency respectively indicate that the virus has picked-up them 
as its choice quite early as they may be evolutionarily advantageous. 
Although the variations in SARS-CoV-2 proteins reported here (based on 
the comparative proteome analysis) would not directly reflect the viral 
transmissibility, pathogenicity, virulence and immunogenicity mecha-
nisms, it clearly pinpoints the effective drug and vaccine targets. 
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